Skip to content
Catalyst

cyanocob(III)alaminWhat was measured

Measured, with no finding

3,745 endpoints

Show what was measuredHide what was measured
  • change in blood hemoglobin at 3 months, vitamin B12 treatment group versus placebo group (also plasma methylmalonic acid, plasma total homocysteine, mean cell volume, symptom scores, Neurological Disability Score)

    no effect, p = 0.18

    Not recorded as a finding: the supporting sentence never names the compound

    P-MMA (P <0.001) or plasma total homocysteine (P <0.001) decreased in the treatment group vs the placebo group, but no significant difference was found in the change of blood hemoglobin (P = 0.18) and mean cell volume (P = 0.71).

    PMID 11468228 · one of two readings recorded this

  • change in blood hemoglobin, treatment group versus placebo, 3 months

    no effect, no significant difference in change of blood hemoglobin, p = 0.18

    Not recorded as a finding: the supporting sentence never names the compound

    P-MMA (P <0.001) or plasma total homocysteine (P <0.001) decreased in the treatment group vs the placebo group, but no significant difference was found in the change of blood hemoglobin (P = 0.18) and mean cell volume (P = 0.71).

    PMID 11468228 · one of two readings recorded this

  • change in blood hemoglobin

    no effect, p = 0.18

    no significant difference was found in the change of blood hemoglobin (P = 0.18)

    PMID 11468228 · one of two readings recorded this

  • change in mean cell volume

    no effect, p = 0.71

    and mean cell volume (P = 0.71)

    PMID 11468228 · one of two readings recorded this

  • change in Neurological Disability Score

    no effect, p = 0.85

    or the Neurological Disability Score (P = 0.85)

    PMID 11468228 · one of two readings recorded this

  • change in symptom score, gastroenterologic symptoms

    no effect, p = 0.32

    gastroenterologic symptoms (P = 0.32)

    PMID 11468228 · one of two readings recorded this

  • change in symptom score, neurologic symptoms

    no effect, p = 0.21

    neurologic symptoms (P = 0.21)

    PMID 11468228 · one of two readings recorded this

  • change in symptom score, symptoms of anemia

    no effect, p = 0.63

    Changes in symptom scores did not differ between the groups for symptoms of anemia (P = 0.63)

    PMID 11468228 · one of two readings recorded this

  • plasma methylmalonic acid (P-MMA)

    decreases, p = 0.001

    P-MMA (P <0.001) or plasma total homocysteine (P <0.001) decreased in the treatment group vs the placebo group

    PMID 11468228 · one of two readings recorded this

  • plasma total homocysteine

    decreases, p = 0.001

    P-MMA (P <0.001) or plasma total homocysteine (P <0.001) decreased in the treatment group vs the placebo group

    PMID 11468228 · one of two readings recorded this

  • disability

    decreases, p = 0.0002

    However, comparison between groups at the end of the treatment period showed a statistically significant difference in favour of the active treatment both for VAS and DQ (p < 0.0001 and p < 0.0002, respectively)

    PMID 11558625 · one of two readings recorded this

  • low back pain intensity on a visual analogic scale (VAS) and Disability Questionnaire, intramuscular vitamin B12

    between-group difference in favour of active treatment for VAS and DQ

    Not recorded as a finding: the direction is carried only as a signed number

    However, comparison between groups at the end of the treatment period showed a statistically significant difference in favour of the active treatment both for VAS and DQ (p < 0.0001 and p < 0.0002, respectively).

    PMID 11558625 · one of two readings recorded this

  • pain and disability

    decreases

    Both treatment groups experienced a sharp decrease in pain and disability

    PMID 11558625 · one of two readings recorded this

  • pain intensity

    decreases, p = 0.0001

    However, comparison between groups at the end of the treatment period showed a statistically significant difference in favour of the active treatment both for VAS and DQ (p < 0.0001 and p < 0.0002, respectively)

    PMID 11558625 · one of two readings recorded this

  • paracetamol consumption

    decreases, p = 0.0001

    Consumption of paracetamol proved significantly higher in the placebo group than in the active treatment (p < 0.0001)

    PMID 11558625 · one of two readings recorded this

  • health-related quality of life

    decreases, p = 0.001

    The participants reported a significantly worser HRQOL than the age- and sex-matched Danish general population (P < 0.001)

    PMID 12542554 · one of two readings recorded this

  • general health dimension

    increases, p = 0.03

    A significant improvement was found only in general health when compared with the placebo group (P = 0.03)

    PMID 12542554 · one of two readings recorded this

  • health-related quality of life by the SF-36 questionnaire, reported per health dimension (eight dimensions), change from baseline to 3 months after weekly vitamin B-12 injections versus placebo

    increases, p = 0.03

    Not recorded as a finding: every result is a subgroup, with no whole-population estimate

    A significant improvement was found only in general health when compared with the placebo group (P = 0.03).

    PMID 12542554 · one of two readings recorded this

  • seven of eight SF-36 health dimensions

    no effect

    no change was observed after treatment with vitamin B-12 for seven of eight health dimensions

    PMID 12542554 · one of two readings recorded this

  • SF-36 health-related quality of life, general health dimension, change over 3 months

    increases, significant improvement in general health versus placebo, p = 0.03

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    A significant improvement was found only in general health when compared with the placebo group (P = 0.03).

    PMID 12542554 · one of two readings recorded this

  • cognitive function in people with dementia and low serum vitamin B12, instrument not stated

    no effect

    Not recorded as a finding: the paper never states the instrument the node requires

    From the two included studies (Seal 2002; Fourniere 1997) of people with dementia and low serum vitamin B12 levels, there was no statistically significant evidence of treatment effect, vitamin B12 supplementation compared with placebo, on cognitive function.

    PMID 12918012 · one of two readings recorded this

  • cognitive function

    no effect

    there was no statistically significant evidence of treatment effect, vitamin B12 supplementation compared with placebo, on cognitive function

    PMID 12918012 · one of two readings recorded this

  • change in serum cobalamin concentration across time

    increases, p = 0.0001

    The increase in each group across time was statistically significant (P = 0.0001, differences [95% confidence intervals] 194.2 (114.5, 273.9), 178.3 (104.2, 252.4), and 195.1 (135.0, 255.2) pmol l-1, respectively)

    PMID 14616423 · one of two readings recorded this

  • change in serum cobalamin concentration across time

    increases, p = 0.0001

    The increase in each group across time was statistically significant (P = 0.0001, differences [95% confidence intervals] 194.2 (114.5, 273.9), 178.3 (104.2, 252.4), and 195.1 (135.0, 255.2) pmol l-1, respectively)

    PMID 14616423 · one of two readings recorded this

  • change in serum cobalamin concentration across time

    increases, p = 0.0001

    The increase in each group across time was statistically significant (P = 0.0001, differences [95% confidence intervals] 194.2 (114.5, 273.9), 178.3 (104.2, 252.4), and 195.1 (135.0, 255.2) pmol l-1, respectively)

    PMID 14616423 · one of two readings recorded this

  • serum cobalamin concentration after 4 weeks of sublingual or oral cobalamin 500 ug daily versus oral vitamin B complex

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    There was no significant difference in concentrations between the treatment groups.

    PMID 14616423 · one of two readings recorded this

  • serum cobalamin concentration after 4 weeks, sublingual 500 ug cobalamin versus oral 500 ug cobalamin versus oral vitamin B complex

    no effect

    Not recorded as a finding: the comparison was against another active treatment

    There was no significant difference in concentrations between the treatment groups.

    PMID 14616423 · one of two readings recorded this

  • serum cobalamin concentration after 4 weeks, sublingual versus oral 500 ug cobalamin versus oral B-complex

    no effect

    Not recorded as a finding: the comparison was against another active treatment

    There was no significant difference in concentrations between the treatment groups.

    PMID 14616423 · one of two readings recorded this

  • serum cobalamin concentration (pmol/l) after 4 weeks of sublingual versus oral cobalamin 500 ug versus oral B-complex

    no effect

    Not recorded as a finding: this platform holds no node for the endpoint

    There was no significant difference in concentrations between the treatment groups.

    PMID 14616423 · one of two readings recorded this

  • serum cobalamin concentration

    n = 30

    Serum cobalamin concentrations before treatment were 94 +/- 30 pmol l-1, 108 +/- 17 pmol l-1 and 98 +/- 14 pmol l-1 in the sublingual B12, oral B12 and oral B-complex groups, respectively

    PMID 14616423 · one of two readings recorded this

  • serum cobalamin concentration

    no effect, n = 30

    After 4 weeks, concentrations rose to 288 +/- 74 pmol l-1, 286 +/- 87 pmol l-1 and 293 +/- 78 pmol l-1, respectively

    PMID 14616423 · one of two readings recorded this

  • hearing thresholds and TTS2 in control group after 8 days

    no effect

    After 8 days of treatment, the control group showed the same hearing thresholds and TTS2 degrees

    PMID 15198380 · one of two readings recorded this

  • noise-induced temporary threshold shift (TTS2) at 3 and 4 kHz

    decreases

    TTS2 decreased significantly at 3 and 4kHz when cobalamin was used to increase the serum concentration of vitamin B12 to > 2350 pg/ml

    PMID 15198380 · one of two readings recorded this

  • noise-induced temporary threshold shift (TTS2) at 3 kHz

    decreases

    a protective effect at 3 kHz in the experimental group was evident when compared with the placebo group

    PMID 15198380 · one of two readings recorded this

  • serum vitamin B12 concentration

    increases

    At the end of treatment, the serum vitamin B12 concentration was significantly increased in the experimental group

    PMID 15198380 · one of two readings recorded this

  • change in cognitive function by total CAMCOG score (Cambridge Cognitive Examination), and depression score on the Major Depression Inventory, baseline to 3 months; MMSE and a 12-words learning test were also administered but no MMSE result is stated

    total CAMCOG score, P = 0.43, p = 0.43

    Not recorded as a finding: this platform holds no node for the endpoint

    No improvement was found in cognitive function comparing the treatment and placebo group (total CAMCOG score: P = 0.43), nor among individuals with only slightly impaired cognitive function (n = 44, total CAMCOG score: P = 0.42).

    PMID 15337331 · one of two readings recorded this

  • change in depression score

    no effect, p = 0.18

    The treatment group did not improve in depression score as compared to the placebo group (P = 0.18)

    PMID 15337331 · one of two readings recorded this

  • change in total CAMCOG score

    no effect, p = 0.43

    No improvement was found in cognitive function comparing the treatment and placebo group (total CAMCOG score: P = 0.43)

    PMID 15337331 · one of two readings recorded this

  • change in total CAMCOG score

    no effect, p = 0.42, n = 44

    nor among individuals with only slightly impaired cognitive function (n = 44, total CAMCOG score: P = 0.42)

    PMID 15337331 · one of two readings recorded this

  • prevalence of cognitive impairment at baseline by CAMCOG

    At baseline 78 (56%) individuals had cognitive impairment judged from the CAMCOG score and 40 (29%) according to the MMSE; 18 (13%) individuals had symptoms of depression.

    PMID 15337331 · one of two readings recorded this

  • prevalence of cognitive impairment at baseline by MMSE

    At baseline 78 (56%) individuals had cognitive impairment judged from the CAMCOG score and 40 (29%) according to the MMSE; 18 (13%) individuals had symptoms of depression.

    PMID 15337331 · one of two readings recorded this

  • prevalence of symptoms of depression at baseline

    At baseline 78 (56%) individuals had cognitive impairment judged from the CAMCOG score and 40 (29%) according to the MMSE; 18 (13%) individuals had symptoms of depression.

    PMID 15337331 · one of two readings recorded this

  • total CAMCOG score (Cambridge Cognitive Examination), change from baseline to 3 months; also Major Depression Inventory score

    p = 0.43

    Not recorded as a finding: this platform holds no node for the endpoint

    No improvement was found in cognitive function comparing the treatment and placebo group (total CAMCOG score: P = 0.43), nor among individuals with only slightly impaired cognitive function (n = 44, total CAMCOG score: P = 0.42).

    PMID 15337331 · one of two readings recorded this

  • autonomic symptoms

    decreases

    In three studies, methylcobalamin therapy improved autonomic symptoms

    PMID 16008162 · one of two readings recorded this

  • somatic symptoms (pain and paresthesia)

    decreases

    Both the vitamin B12 combination and pure methylcobalamin had beneficial effects on somatic symptoms, such as pain and paresthesia

    PMID 16008162 · one of two readings recorded this

  • vibration perception and electrophysiological measures

    unclear

    Effects on vibration perception and electrophysiological measures were not consistent

    PMID 16008162 · one of two readings recorded this

  • fraction of pemetrexed excreted unchanged in urine

    The Fe averaged 0.752 (range, 0.645–0.827)

    PMID 16940981 · one of two readings recorded this

  • maximum tolerated dose of pemetrexed with FA/VB12

    n = 6

    As two DLTs were observed, the 1200 mg m−2 dose level was considered as the MTD

    PMID 16940981 · one of two readings recorded this

  • mean elimination half-life of pemetrexed

    no effect

    The overall mean t1/2 is approximately 2.74 h and was essentially similar across all dose groups (range, 2.28–3.62 h)

    PMID 16940981 · one of two readings recorded this

  • partial response

    n = 23

    Partial responses (PRs) were observed in four patients with NSCLC (one patient each at 500, 700, 800, and 1200 mg m−2) and one patient with thymoma at 500 mg m−2

    PMID 16940981 · one of two readings recorded this

  • patients evaluable for tumour response

    n = 23

    In this study, 23 of the 31 patients were evaluable for response by RECIST criteria

    PMID 16940981 · one of two readings recorded this

  • patients with rash in cycle 1

    n = 25

    At cycle 1, 25 patients experienced rash

    PMID 16940981 · one of two readings recorded this

  • recommended dose of pemetrexed with FA/VB12

    The RD for subsequent phase II studies was then evaluated to be pemetrexed 1000 mg m−2

    PMID 16940981 · one of two readings recorded this

  • duration of outbreaks

    decreases, p = 0.05

    The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood

    PMID 19124628 · one of two readings recorded this

  • duration of outbreaks

    decreases, p = 0.05

    The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood

    PMID 19124628 · one of two readings recorded this

  • level of pain in recurrent aphthous stomatitis at 5 and 6 months of sublingual vitamin B12; also outbreak duration and number of ulcers

    decreases

    Not recorded as a finding: the paper never states the instrument the node requires

    The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood.

    PMID 19124628 · one of two readings recorded this

  • level of pain in recurrent aphthous stomatitis, instrument not named in the abstract

    decreases, reduced at 5 and 6 months of treatment

    Not recorded as a finding: the paper never states the instrument the node requires

    The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood.

    PMID 19124628 · one of two readings recorded this

  • level of pain

    decreases, p = 0.05

    The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood

    PMID 19124628 · one of two readings recorded this

  • level of pain

    decreases, p = 0.05

    The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood

    PMID 19124628 · one of two readings recorded this

  • number of ulcers

    decreases, p = 0.05

    The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood

    PMID 19124628 · one of two readings recorded this

  • number of ulcers

    decreases, p = 0.05

    The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P < .05) at 5 and 6 months of treatment with vitamin B(12), regardless of initial vitamin B(12) levels in the blood

    PMID 19124628 · one of two readings recorded this

  • participants reaching no aphthous ulcers status

    During the last month of treatment a significant number of participants in the intervention group reached "no aphthous ulcers status" (74.1% vs 32.0%; P < .01)

    PMID 19124628 · one of two readings recorded this

  • participants reaching no aphthous ulcers status

    increases, p = 0.01

    During the last month of treatment a significant number of participants in the intervention group reached "no aphthous ulcers status" (74.1% vs 32.0%; P < .01)

    PMID 19124628 · one of two readings recorded this

  • pain score on a visual analogue scale in painful diabetic neuropathy, parenteral vitamin B12 versus nortriptyline

    decreases, decrease of 3.66 units versus 0.84 units

    Not recorded as a finding: the comparison was against another active treatment

    After treatment, the pain score based on a visual analogue scale decreased 3.66 units in the vitamin B(12) group and 0.84 units in the nortriptyline group (P <0.001).

    PMID 19212856 · both readings recorded this

  • pain score

    decreases, p = 0.001

    the pain score based on a visual analogue scale decreased 3.66 units in the vitamin B(12) group and 0.84 units in the nortriptyline group (P <0.001)

    PMID 19212856 · one of two readings recorded this

  • paresthesia score

    decreases, p = 0.001

    the paresthesia score decreased 2.98 units versus 1.06 units (P <0.001)

    PMID 19212856 · one of two readings recorded this

  • tingling sensation

    decreases, p = 0.001

    The decrements of tingling sensation were 3.48 units versus 1.02 units (P <0.001)

    PMID 19212856 · one of two readings recorded this

  • vibration, position, pinprick and nerve conduction parameters

    no effect

    Changes in vibration, position, pinprick and nerve conduction parameters were not significant in two groups

    PMID 19212856 · one of two readings recorded this

  • B12 deficiency at baseline

    At baseline 48% participants were B12 deficient

    PMID 20216560 · one of two readings recorded this

  • baseline-adjusted change in plasma tHcy

    no effect

    The B0 group showed a non-significant rise of 1.2 (95% CI: −0.5, 2.8) μmol/L

    PMID 20216560 · one of two readings recorded this

  • baseline-adjusted change in plasma tHcy

    decreases

    7.1 (95% CI: −8.9, −5.4) μmol/L in the B10 group

    PMID 20216560 · one of two readings recorded this

  • baseline-adjusted change in plasma tHcy

    decreases

    The baseline-adjusted fall was 5.9 (95% CI: −7.8, −4.1) μmol/L in the B2 group

    PMID 20216560 · one of two readings recorded this

  • change in plasma tHcy

    decreases

    F0 2.8 (95% CI: −4.3, −1.2) μmol/L

    PMID 20216560 · one of two readings recorded this

  • change in plasma tHcy

    decreases

    F200 4.8 (95% CI: −6.3, −3.3) μmol/L

    PMID 20216560 · one of two readings recorded this

  • interaction between B12 and folic acid on change in plasma tHcy

    no effect, p = 0.14

    There was no significant interaction between the effects of B12 and folic acid supplementation on change in plasma tHcy concentration (P=0.14

    PMID 20216560 · one of two readings recorded this

  • number needed to treat for hyperhomocysteinemia

    The number needed to treat (NNT) was 4 for B2, 2 for B10 and 10 for F200 group

    PMID 20216560 · one of two readings recorded this

  • number needed to treat for hyperhomocysteinemia

    The number needed to treat (NNT) was 4 for B2, 2 for B10 and 10 for F200 group

    PMID 20216560 · one of two readings recorded this

  • number needed to treat for hyperhomocysteinemia

    The number needed to treat (NNT) was 4 for B2, 2 for B10 and 10 for F200 group

    PMID 20216560 · one of two readings recorded this

  • plasma total homocysteine (tHcy), fluorescence polarization immunoassay; plasma vitamin B12 and folate, microbiological assay

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    The baseline-adjusted fall was 5.9 (95% CI: −7.8, −4.1) μmol/L in the B2 group and 7.1 (95% CI: −8.9, −5.4) μmol/L in the B10 group (not significantly different).

    PMID 20216560 · one of two readings recorded this

  • plasma vitamin B12 concentration, microbiological assay (L. leichmanii)

    increases

    Not recorded as a finding: the only sentence naming the rise is a within-arm statement and the no-B12 arm also rose 33% above baseline, so no between-arm contrast sentence exists

    Plasma B12 concentrations increased significantly in those who received B12 supplements.

    PMID 20216560 · both readings recorded this

  • proportion hyperhomocysteinemic

    increases, p = 0.02

    in the B0 group it increased from 44% to 56% (P=0.02)

    PMID 20216560 · one of two readings recorded this

  • proportion hyperhomocysteinemic

    decreases

    in the B10 group from 56% to 21% (P<0.000)

    PMID 20216560 · one of two readings recorded this

  • proportion hyperhomocysteinemic

    decreases, p = 0.02

    in the B2 group the proportion of hyperhomocysteinemic participants fell from 52% to 39% (P=0.02)

    PMID 20216560 · one of two readings recorded this

  • proportion hyperhomocysteinemic

    no effect, p = 0.07

    In the F0 group the proportion of hyperhomocysteinemic participants fell from 53% to 44%, P=0.07

    PMID 20216560 · one of two readings recorded this

  • proportion hyperhomocysteinemic

    decreases, p = 0.003

    in the F200 group from 48% to 34%, P=0.003

    PMID 20216560 · one of two readings recorded this

  • remaining B12 deficiency after supplementation (B10)

    After 12 mo of supplementation 6% of the B2 and 2% of the B10 group remained B12 deficient

    PMID 20216560 · one of two readings recorded this

  • remaining B12 deficiency after supplementation (B2)

    After 12 mo of supplementation 6% of the B2 and 2% of the B10 group remained B12 deficient

    PMID 20216560 · one of two readings recorded this

  • rise in plasma folate from baseline

    increases

    increased by 112% in those who received folic acid (F200) and by 18.8% in the group who did not (F0)

    PMID 20216560 · one of two readings recorded this

  • rise in plasma folate from baseline

    increases

    Plasma folate concentrations increased by 112% in those who received folic acid (F200)

    PMID 20216560 · one of two readings recorded this

  • rise in plasma vitamin B12 from baseline

    increases

    Participants who did not receive B12 (B0) also showed a rise in plasma B12 concentration (33% above baseline) after 12 mo

    PMID 20216560 · one of two readings recorded this

  • rise in plasma vitamin B12 from baseline

    increases

    119% in those who received 10 μg (B10)

    PMID 20216560 · one of two readings recorded this

  • rise in plasma vitamin B12 from baseline

    increases

    At 12 mo the rise was 64% in those who received 2 μg (B2)

    PMID 20216560 · one of two readings recorded this

  • Prostate cancer risk, highest versus lowest quartile of holo-haptocorrin

    increases, p = 0.01

    highest versus lowest quartile of holo-haptocorrin OR = 1.27 (1.04-1.56); P(trend) = 0.01

    PMID 20501771 · one of two readings recorded this

  • Prostate cancer risk, highest versus lowest quartile of plasma vitamin B12

    increases, p = 0.06

    highest versus lowest quartile of B(12) odds ratio (OR) = 1.17 (95% confidence interval, 0.95-1.43); P(trend) = 0.06

    PMID 20501771 · one of two readings recorded this

  • Prostate cancer risk, pooled meta-analysis, per 10 nmol/L increase in circulating folate

    increases, p = 0.02

    OR = 1.18 (1.00-1.40) per 10 nmol/L; P = 0.02

    PMID 20501771 · one of two readings recorded this

  • Prostate cancer risk, pooled meta-analysis, per 10 nmol/L increase in circulating folate

    no effect, p = 0.2

    OR = 1.11 (0.96-1.28) per 10 nmol/L; P = 0.2

    PMID 20501771 · one of two readings recorded this

  • Prostate cancer risk, pooled meta-analysis, per 100 pmol/L increase in circulating B12

    increases, p = 0.002

    pooled OR = 1.10 (1.01-1.19) per 100 pmol/L increase in B(12); P = 0.002

    PMID 20501771 · one of two readings recorded this

  • adherence, proportion of days with correct medication

    no effect

    Doses and proportion of days with correct medication were 27.4 intakes and 93.5% of days for the oral B12 group and 28.4 intakes and 94.4% of days for the placebo group

    PMID 21232119 · one of two readings recorded this

  • baseline serum homocysteine

    n = 50

    Mean (SD) | 18.3 μmol/l (SD = 6.6)* | 15.0 μmol/l (SD = 5.3)*

    PMID 21232119 · one of two readings recorded this

  • baseline serum MMA

    n = 50

    Mean (SD) | 0.43 μmol/l (SD = 0.25)* | 0.41 μmol/l (SD = 0.24)*

    PMID 21232119 · one of two readings recorded this

  • baseline serum vitamin B12

    n = 50

    Mean (SD) | 164 pM/l (SD = 24) | 154 pM/l (SD = 20)

    PMID 21232119 · one of two readings recorded this

  • hematocrit change vs placebo

    no effect, p = 0.502, n = 50

    Hematocrite (% red cells) | 39.6 (4.1); 26 | 40.1 (4.0); 26 | 39.7 (4.6); 24 | 39.4 (4.6); 22 | -0.4 (CI95% -1.7 to 0.8; p = 0.502) | 0.5 (CI95% -1.0 to 2.1; p = 0.475)

    PMID 21232119 · one of two readings recorded this

  • hematocrit change vs placebo

    no effect, p = 0.475, n = 48

    Hematocrite (% red cells) | 39.6 (4.1); 26 | 40.1 (4.0); 26 | 39.7 (4.6); 24 | 39.4 (4.6); 22 | -0.4 (CI95% -1.7 to 0.8; p = 0.502) | 0.5 (CI95% -1.0 to 2.1; p = 0.475)

    PMID 21232119 · one of two readings recorded this

  • mean corpuscular volume change vs placebo

    no effect, p = 0.674, n = 50

    MCV (fl) | 89.8 (6.9); 26 | 89.0 (7.0); 26 | 92.8 (7.0); 24 | 92.6 (7.6); 22 | -0.4 (CI95% -2.2 to 1.4; p = 0.674) | -0.1 (CI95% -2.3 to 2.2; p = 0.950)

    PMID 21232119 · one of two readings recorded this

  • mean corpuscular volume change vs placebo

    no effect, p = 0.95, n = 48

    MCV (fl) | 89.8 (6.9); 26 | 89.0 (7.0); 26 | 92.8 (7.0); 24 | 92.6 (7.6); 22 | -0.4 (CI95% -2.2 to 1.4; p = 0.674) | -0.1 (CI95% -2.3 to 2.2; p = 0.950)

    PMID 21232119 · one of two readings recorded this

  • Mini Mental State Examination change vs placebo

    no effect, p = 0.432, n = 47

    MMSE (score 0-30) | - | 27.8 (2.3); 26 | - | 28.1 (2.2); 21 | - | -0.4 (CI95% -1.3 to 0.6; p = 0.432)

    PMID 21232119 · one of two readings recorded this

  • number needed to treat for improving MMA

    the NNT for improving MMA serum concentration at one month was 2.6 patients (95% CI 1.7 to 9.4)

    PMID 21232119 · one of two readings recorded this

  • proportion of patients with normal MMA at baseline

    At baseline, 21.7% of patients had MMA levels that were considered normal (less than 0.26 μmol/l)

    PMID 21232119 · one of two readings recorded this

  • relative improvement of homocysteine toward healthy mean

    no effect, p = 0.844

    Hcys (μmol/l) Reduction | 1.8% (CI95% -16.4:20.0; p = 0.844) | 6.7% (CI95% -11.3:24.7; p = 0.455)

    PMID 21232119 · one of two readings recorded this

  • relative improvement of homocysteine toward healthy mean

    no effect, p = 0.455

    Hcys (μmol/l) Reduction | 1.8% (CI95% -16.4:20.0; p = 0.844) | 6.7% (CI95% -11.3:24.7; p = 0.455)

    PMID 21232119 · one of two readings recorded this

  • relative improvement of MMA toward healthy mean

    decreases, p = 0.001

    MMA (μmol/l) Reduction | 48.7% (CI95% 29.0:68.3; p < 0.001) | 0.2% (CI95% -17.8:18.3; p = 0.979)

    PMID 21232119 · one of two readings recorded this

  • relative improvement of MMA toward healthy mean

    no effect, p = 0.979

    MMA (μmol/l) Reduction | 48.7% (CI95% 29.0:68.3; p < 0.001) | 0.2% (CI95% -17.8:18.3; p = 0.979)

    PMID 21232119 · one of two readings recorded this

  • relative improvement of serum cobalamin toward healthy mean

    increases, p = 0.001

    Serum cobalamin (pM/l) Increase | 26.9% (CI95% 13.9:39.8; p < 0.001) | 14.1% (CI95% -3.1:31.3; p = 0.105)

    PMID 21232119 · one of two readings recorded this

  • relative improvement of serum cobalamin toward healthy mean

    no effect, p = 0.105

    Serum cobalamin (pM/l) Increase | 26.9% (CI95% 13.9:39.8; p < 0.001) | 14.1% (CI95% -3.1:31.3; p = 0.105)

    PMID 21232119 · one of two readings recorded this

  • serum cobalamin change vs placebo

    increases, p = 0.001, n = 49

    Serum cobalamin (pM/l) | 263.4 (89.8); 25 | 202.6 (56.3); 23 | 154.5 (41.1); 24 | 162.9 (39.8); 23 | 101.6 (CI95% 60.1 to 143.2; p < 0.001) | 35.0 (CI95% 6.4 to 63.5; p = 0.018)

    PMID 21232119 · one of two readings recorded this

  • serum cobalamin change vs placebo

    increases, p = 0.018, n = 46

    Serum cobalamin (pM/l) | 263.4 (89.8); 25 | 202.6 (56.3); 23 | 154.5 (41.1); 24 | 162.9 (39.8); 23 | 101.6 (CI95% 60.1 to 143.2; p < 0.001) | 35.0 (CI95% 6.4 to 63.5; p = 0.018)

    PMID 21232119 · one of two readings recorded this

  • serum methylmalonic acid (GC-MS with isotopic dilution), change from baseline at one month, oral vitamin B12 1000 ug daily versus placebo; also serum B12 (radioimmunoassay) and total homocysteine (HPLC)

    decreases, relative improvement toward healthy mean 48.7% (95% CI 29.0 to 68.3) over placebo

    Not recorded as a finding: the supporting sentence never names the compound

    At one month, patients undergoing vitamin B12 treatment decreased their mean deficit by 48.7% (95% CI 29.0 to 68.3) over placebo.

    PMID 21232119 · one of two readings recorded this

  • serum MMA change vs placebo

    decreases, p = 0.001, n = 45

    MMA (μmol/l) | 0.23 (0.08); 22 | 0.41 (0.30); 19 | 0.37 (0.14); 23 | 0.35 (0.16); 22 | - 0.13 (CI95% -0.19 to -0.06; p < 0.001) | 0.03 (CI95% -0.12 to 0.17; p = 0.686)

    PMID 21232119 · one of two readings recorded this

  • serum MMA change vs placebo

    no effect, p = 0.686, n = 41

    MMA (μmol/l) | 0.23 (0.08); 22 | 0.41 (0.30); 19 | 0.37 (0.14); 23 | 0.35 (0.16); 22 | - 0.13 (CI95% -0.19 to -0.06; p < 0.001) | 0.03 (CI95% -0.12 to 0.17; p = 0.686)

    PMID 21232119 · one of two readings recorded this

  • serum MMA per-protocol analysis

    no effect, p = 0.832

    Per-protocol analysis also confirmed the absence of a difference in mean MMA concentrations between the placebo and treatment groups at four months (-0.02 μmol/l; 95% CI -0.16 to 0.13; p = 0.832)

    PMID 21232119 · one of two readings recorded this

  • total homocysteine change vs placebo

    no effect, p = 0.95, n = 45

    Hcys (μmol/l) | 16.5 (6.1); 22 | 17.1 (7.5); 19 | 13.9 (4.3); 23 | 15.6 (5.8); 22 | 0.04 (CI95% -1.2 to 1.3; p = 0.950) | -1.0 (CI95% -4.0 to 2.0; p = 0.502)

    PMID 21232119 · one of two readings recorded this

  • total homocysteine change vs placebo

    no effect, p = 0.502, n = 41

    Hcys (μmol/l) | 16.5 (6.1); 22 | 17.1 (7.5); 19 | 13.9 (4.3); 23 | 15.6 (5.8); 22 | 0.04 (CI95% -1.2 to 1.3; p = 0.950) | -1.0 (CI95% -4.0 to 2.0; p = 0.502)

    PMID 21232119 · one of two readings recorded this

  • CD4+ cell percent < 25 by HAART status

    p = 0.001, n = 199

    Thirteen out of 40 children (32.5%) who were on HAART had CD4+ cell percent < 25 compared to 100/159 (63.5%) who were HAART naïve, p = 0.001

    PMID 21600005 · one of two readings recorded this

  • CD4+ count

    no effect, n = 214

    6 months | 1039 (725 - 1358) | 1043 (704 - 1484)

    PMID 21600005 · one of two readings recorded this

  • change in haemoglobin

    n = 214

    Change | 0.3 (-0.4 - 0.9) | 0.6 (-0.2 - 1.4)

    PMID 21600005 · one of two readings recorded this

  • change in serum folate concentration

    n = 214

    Change | 8.0 (-0.3 - 17.1) | -0.6 (-3.5 - 5.8)

    PMID 21600005 · one of two readings recorded this

  • change in serum vitamin B12 concentration

    n = 214

    Change | 90.5 (-0.8 - 203.5) | 10.0 (-73.8 - 83.8)

    PMID 21600005 · one of two readings recorded this

  • haemoglobin

    n = 214

    6 months | 10.9 (9.4 - 11.7) | 10.6 (9.6 - 11.7)

    PMID 21600005 · one of two readings recorded this

  • low folate association with age under 24 months

    increases, n = 214

    Age < 24 months | 70 | 27 (38.6) | 1.6 (1.1 - 2.4) | 2.2 (1.1 - 4.5)

    PMID 21600005 · one of two readings recorded this

  • low folate association with haemoglobin < 11 g/dl

    no effect, n = 214

    Haemoglobin < 11 g/dl | 127 | 45 (35.4) | 1.8 (1.1 - 2.9) | 1.9 (0.9 - 4.6)

    PMID 21600005 · one of two readings recorded this

  • low folate association with male sex

    increases, n = 214

    Male | 100 | 36 (36.0) | 1.6 (1.0 - 2.4) | 2.1 (1.1 - 4.0)

    PMID 21600005 · one of two readings recorded this

  • low folate status at 6 months (MV vs MMS)

    n = 214

    Five children (11.4%) were supplemented with MMS and 39 (88.6%) MV; Odds ratio 10.8 (95% CI; 4.1 - 28.9)

    PMID 21600005 · one of two readings recorded this

  • low vitamin B12 association with male sex

    no effect, n = 214

    Male | 100 | 33 (33.0) | 1.4 (0.9 - 2.1) | 1.6 (0.8 - 3.1)

    PMID 21600005 · one of two readings recorded this

  • low vitamin B12 status at 6 months (MV vs MMS)

    n = 214

    The odds ratio was 4.5 (95% CI; 2.0 - 10.0)

    PMID 21600005 · one of two readings recorded this

  • prevalence of low folate at baseline

    n = 214

    and 62 (29.0%) had low folate concentrations less than 13.4 nmol/L

    PMID 21600005 · one of two readings recorded this

  • prevalence of low vitamin B12 at baseline

    n = 214

    Overall, 60 children (28.0%) had low vitamin B12 concentrations less than 221.0 pmol/L

    PMID 21600005 · one of two readings recorded this

  • serum folate concentration

    n = 214

    6 months | 27.7 (21.1 - 33.4) | 16.5 (11.7 - 22.1)

    PMID 21600005 · one of two readings recorded this

  • serum folate concentration

    increases, p = 0.04, n = 19

    The median (IQR) folate concentrations increased from 18.6 (13.8 - 23.9) to 25.0 (21.3 - 32.9) nmol/L, p = 0.040

    PMID 21600005 · one of two readings recorded this

  • serum folate concentration

    increases, p = 0.001, n = 104

    Similarly folate concentrations increased from 17.3 (13.5 - 26.6) to 27.7 (21.1 - 33.4) nmol/L and this difference was also significant, p < 0.001

    PMID 21600005 · one of two readings recorded this

  • serum vitamin B12 and folate concentrations at 6 months, electrochemiluminescence immunoassay; haemoglobin; CD4+ count

    increases

    Not recorded as a finding: the intervention held more than the compound

    Low vitamin B12 and folate concentrations were more frequent in the MV supplemented group.

    PMID 21600005 · one of two readings recorded this

  • serum vitamin B12 concentration

    n = 214

    6 months | 401.5 (264.3 - 518.8) | 288.5 (198.8 - 391.0)

    PMID 21600005 · one of two readings recorded this

  • serum vitamin B12 concentration

    increases, p = 0.002, n = 19

    In this stratum the median (IQR) concentration of vitamin B12 in the MMS arm at baseline was 262.0 (215.0 - 342.0) compared to 453.0 (261.0 - 594.0) pmol/L at 6 months, p = 0.002

    PMID 21600005 · one of two readings recorded this

  • serum vitamin B12 concentration

    increases, n = 104

    Following supplementation with multiple micronutrients (MMS) vitamin B12 concentrations increased from a median (IQR) of 285.5 (216.5 - 371.8) to 401.5 (264.3 - 518.8) pmol/L at 6 months

    PMID 21600005 · one of two readings recorded this

  • Carotid intima-media thickness (IMT)

    decreases, p = 0.05

    carotid IMT (0.65±0.09mm, P<0.05)

    PMID 22659999 · one of two readings recorded this

  • Carotid intima-media thickness (IMT)

    decreases, p = 0.05

    carotid IMT decreased (0.69±0.09mm to 0.67±0.09mm; p<0.05)

    PMID 22659999 · one of two readings recorded this

  • HDL cholesterol

    no effect

    HDL-C (mmol/l) | l.4±0.3 | 1.4±0.4 | 1.4±0.3

    PMID 22659999 · one of two readings recorded this

  • LDL cholesterol

    no effect

    LDL-C (mmol/l) | 2.5±0.8 | 2.4±0.7 | 2.4±0.8

    PMID 22659999 · one of two readings recorded this

  • Glucose

    no effect

    Glucose (mmol/l) | 5.l±0.9 | 5.1±1.0 | 5.1±0.6

    PMID 22659999 · one of two readings recorded this

  • Association of change in serum vitamin B-12 with change in FMD

    increases, p = 0.02

    On multivariate analysis, changes in vitamin B-12 (β=0.25; p=0.02) but not homocysteine level correlated with changes in FMD

    PMID 22659999 · one of two readings recorded this

  • brachial artery flow-mediated dilation (FMD, ultrasound) and carotid intima-media thickness (ultrasound) in vegetarians with subnormal B12 status; oral vitamin B-12 500 ug/day (form not stated) versus placebo, 12-week double-blind crossover; also blood pressure, glucose, LDL-C, HDL-C reported as unchanged after B-12

    increases, FMD 6.3 +/- 1.8% to 6.9 +/- 1.9%, p<0.0001 after vitamin B-12 but not after placebo (pre-to-post change within each crossover period; no between-treatment test reported in the Results)

    Not recorded as a finding: the result compares a group with itself, not with a control

    Brachial FMD significantly increased (6.3±1.8% to 6.9±1.9%; p<0.0001) and carotid IMT decreased (0.69±0.09mm to 0.67±0.09mm; p<0.05) after vitamin B-12 but not after placebo treatment.

    PMID 22659999 · one of two readings recorded this

  • Brachial flow-mediated dilation (FMD)

    increases, p = 0.001

    Further improvement in brachial FMD (7.4±1.7%, P <0.001)

    PMID 22659999 · one of two readings recorded this

  • Brachial flow-mediated dilation (FMD)

    increases, p = 0.0001

    Brachial FMD significantly increased (6.3±1.8% to 6.9±1.9%; p<0.0001)

    PMID 22659999 · one of two readings recorded this

  • Diastolic blood pressure

    no effect

    Diastolic BP (mmHg) | 8l±l2 | 78±9 | 79±10

    PMID 22659999 · one of two readings recorded this

  • Glyceryl trinitrate (GTN) response

    no effect

    GTN (%) | 17.1±2.7 | 18.2±2.0 | 18.8±2.1

    PMID 22659999 · one of two readings recorded this

  • Plasma homocysteine

    decreases

    Homocysteine (µmol/l) | l6.7±ll.0 | 13.1±5.0 * | 11.3±6.0 **

    PMID 22659999 · one of two readings recorded this

  • Reactive hyperemia

    no effect

    Reactive Hyperemia (%) | 883.9±97.l | 900.7±99.9 | 920.7±75.5

    PMID 22659999 · one of two readings recorded this

  • resting supine systolic and diastolic blood pressure, mmHg (instrument not stated)

    no effect

    Not recorded as a finding: Only sentence is a within-period 'no significant changes' statement beside other endpoints, and the acquisition protocol is a resting supine reading with no device named, so it does not meet the office or unspecified-setting blood pressure node definitions cleanly

    After vitamin B-12 supplementation, there was a significant increase in vitamin B-12 and fall in homocysteine levels but no significant changes in blood pressure, serum glucose or LDL- cholesterol.

    PMID 22659999 · one of two readings recorded this

  • Serum folate

    no effect

    Folate (nmol/l) | 39.4±l0.4 | 39.2±14.2 | 40.0±12.3

    PMID 22659999 · one of two readings recorded this

  • serum glucose after a 14-h fast and LDL-cholesterol, assay not stated

    no effect

    Not recorded as a finding: Same sentence as the blood pressure null: a within-period statement after B-12 only, agentless for the placebo arm, and the glucose assay and LDL derivation are not stated

    After vitamin B-12 supplementation, there was a significant increase in vitamin B-12 and fall in homocysteine levels but no significant changes in blood pressure, serum glucose or LDL- cholesterol.

    PMID 22659999 · one of two readings recorded this

  • Serum vitamin B-12

    increases

    B-l2 (pmol/l) | l34.0±l25.6 | 185.7±145.4 * | 379.6±206.2#

    PMID 22659999 · one of two readings recorded this

  • Systolic blood pressure

    no effect

    Systolic BP (mmHg) | l22±l4 | 117±13 | 117±16

    PMID 22659999 · one of two readings recorded this

  • complete early viral response (undetectable HCV-RNA at 12 weeks)

    increases, p = 0.03

    the rates of complete early viral response (p=0.03)

    PMID 22810757 · one of two readings recorded this

  • end-of-treatment viral response

    increases, p = 0.03

    end-of-treatment viral response (p=0.03)

    PMID 22810757 · one of two readings recorded this

  • IL-28B genotype distribution

    no effect

    Distribution of genotype IL-28B did not differ between the two groups

    PMID 22810757 · one of two readings recorded this

  • rapid viral response (undetectable HCV-RNA at 4 weeks)

    no effect

    Overall, rapid viral response did not differ between the two groups

    PMID 22810757 · one of two readings recorded this

  • sustained viral response (SVR)

    increases, p = 0.001

    and SVR (p=0.001)

    PMID 22810757 · one of two readings recorded this

  • sustained viral response (undetectable serum HCV-RNA 24 weeks after completing treatment) in chronic hepatitis C, pegylated interferon alpha plus ribavirin with or without vitamin B12

    increases, p = 0.001

    Not recorded as a finding: this platform holds no node for the endpoint

    Overall, rapid viral response did not differ between the two groups, whereas the rates of complete early viral response (p=0.03), end-of-treatment viral response (p=0.03) and SVR (p=0.001) were significantly higher in SOC+B12 patients than in SOC patients.

    PMID 22810757 · one of two readings recorded this

  • sustained viral response (undetectable serum HCV-RNA 24 weeks after completing treatment), SOC plus B12 versus SOC alone

    increases, SVR rate significantly higher in SOC+B12 than SOC, p = 0.001

    Not recorded as a finding: this platform holds no node for the endpoint

    Overall, rapid viral response did not differ between the two groups, whereas the rates of complete early viral response (p=0.03), end-of-treatment viral response (p=0.03) and SVR (p=0.001) were significantly higher in SOC+B12 patients than in SOC patients.

    PMID 22810757 · one of two readings recorded this

  • SVR, multivariate analysis, easy-to-treat HCV genotypes

    increases, p = 0.001

    easy-to-treat HCV genotypes (OR=9.00; 95% CI 2.5 to 37.5; p=0.001)

    PMID 22810757 · one of two readings recorded this

  • SVR, multivariate analysis, vitamin B12 supplementation

    increases, p = 0.002

    vitamin B12 supplementation (OR=6.9; 95% CI 2.0 to 23.6; p=0.002)

    PMID 22810757 · one of two readings recorded this

  • SVR rate in carriers of a difficult-to-treat genotype

    increases, p = 0.002

    the SVR rate was also significantly higher in carriers of a difficult-to-treat genotype (p=0.002)

    PMID 22810757 · one of two readings recorded this

  • SVR rate in patients with a high baseline viral load

    increases, p = 0.002

    and in patients with a high baseline viral load (p=0.002)

    PMID 22810757 · one of two readings recorded this

  • equivocal hematologic response

    n = 192

    Another 5 patients had equivocal hematologic responses

    PMID 23262189 · one of two readings recorded this

  • objectively documented hematologic response (MCV decrease by ≥5 fL with stable or improved hemoglobin)

    n = 192

    Only 12 patients had objectively documented hematologic responses: decrease of mean corpuscular volume by ≥5 fL with stable or improved hemoglobin

    PMID 23262189 · one of two readings recorded this

  • objectively documented hematologic response (mean corpuscular volume decrease of at least 5 fL with stable or improved hemoglobin) after intramuscular vitamin B12 injections, retrospective chart review

    18 of 192 patients (9.4%) had data supportive of a clinical response, n = 192

    Not recorded as a finding: this platform holds no node for the endpoint

    Thus, only 18 (9.4%) of 192 patients had data supportive of a clinical response.

    PMID 23262189 · one of two readings recorded this

  • patients with data supportive of a clinical response

    n = 192

    Thus, only 18 (9.4%) of 192 patients had data supportive of a clinical response

    PMID 23262189 · one of two readings recorded this

  • proportion of patients with a documented hematologic response (mean corpuscular volume decrease of at least 5 fL with stable or improved hemoglobin) after intramuscular vitamin B12 injections, retrospective chart review of 192 patients, no control arm

    18 of 192 patients (9.4%) with data supportive of a clinical response, n = 192

    Not recorded as a finding: this platform holds no node for the endpoint

    Thus, only 18 (9.4%) of 192 patients had data supportive of a clinical response.

    PMID 23262189 · one of two readings recorded this

  • energy intake

    AfAm men (2,194 kcal/day) and JpAm women (1,808 kcal/day) reported the lowest energy intake

    PMID 23398393 · one of two readings recorded this

  • energy intake

    AfAm men (2,194 kcal/day) and JpAm women (1,808 kcal/day) reported the lowest energy intake

    PMID 23398393 · one of two readings recorded this

  • energy intake

    NH had the highest energy intakes for men (2,760 kcal/day) and women (2,370 kcal/day)

    PMID 23398393 · one of two readings recorded this

  • energy intake

    NH had the highest energy intakes for men (2,760 kcal/day) and women (2,370 kcal/day)

    PMID 23398393 · one of two readings recorded this

  • mean BMI

    NH men (28.5 kg/m2) and AfAm women (28.4 kg/m2) had the highest mean BMI

    PMID 23398393 · one of two readings recorded this

  • mean BMI

    NH men (28.5 kg/m2) and AfAm women (28.4 kg/m2) had the highest mean BMI

    PMID 23398393 · one of two readings recorded this

  • baseline RBC folate vs 16-week SANS change, lowest tertile

    increases, p = 0.04

    in the lowest tertile (r=.43, p=.04) but not the middle (r=.29, p=.20) or upper (r=.23, p=.29) tertiles

    PMID 23467813 · one of two readings recorded this

  • baseline RBC folate vs 16-week SANS change, middle tertile

    no effect, p = 0.2

    in the lowest tertile (r=.43, p=.04) but not the middle (r=.29, p=.20) or upper (r=.23, p=.29) tertiles

    PMID 23467813 · one of two readings recorded this

  • baseline RBC folate vs 16-week SANS change, upper tertile

    no effect, p = 0.29

    in the lowest tertile (r=.43, p=.04) but not the middle (r=.29, p=.20) or upper (r=.23, p=.29) tertiles

    PMID 23467813 · one of two readings recorded this

  • baseline RBC folate vs baseline SANS, lowest tertile

    decreases, p = 0.01

    Baseline RBC folate correlated inversely with baseline SANS in the lowest tertile (r= -.39, p=.01), but not in the middle (r= -.27, p=.09) or upper (r= -.16, p=.35) tertiles

    PMID 23467813 · one of two readings recorded this

  • baseline RBC folate vs baseline SANS, middle tertile

    no effect, p = 0.09

    Baseline RBC folate correlated inversely with baseline SANS in the lowest tertile (r= -.39, p=.01), but not in the middle (r= -.27, p=.09) or upper (r= -.16, p=.35) tertiles

    PMID 23467813 · one of two readings recorded this

  • baseline RBC folate vs baseline SANS, upper tertile

    no effect, p = 0.35

    Baseline RBC folate correlated inversely with baseline SANS in the lowest tertile (r= -.39, p=.01), but not in the middle (r= -.27, p=.09) or upper (r= -.16, p=.35) tertiles

    PMID 23467813 · one of two readings recorded this

  • change in negative symptoms (SANS), folate plus B12 vs placebo

    decreases, p = 0.02, n = 120

    the main effect of treatment over time became significant (group difference -0.33 per week; 95% CI, -0.62 to -0.05; p=.02)

    PMID 23467813 · one of two readings recorded this

  • change in negative symptoms (SANS), folate plus B12 vs placebo

    no effect, p = 0.15, n = 135

    the difference between folate and placebo groups did not reach significance (-0.21 per week; 95% CI, -0.49 to 0.07; p=.15)

    PMID 23467813 · one of two readings recorded this

  • change in negative symptoms (SANS), folate plus B12 vs placebo

    decreases, p = 0.005, n = 120

    with active treatment conferring a benefit over placebo in the T/T group (treatment group difference -0.59 per week; 95% CI, -0.99 to -0.18; p=.005)

    PMID 23467813 · one of two readings recorded this

  • change in negative symptoms (SANS), folate plus B12 vs placebo

    no effect, p = 0.64, n = 120

    among C allele carriers (treatment group difference +0.09 per week; 95% CI, -0.29 to 0.47; p=.64)

    PMID 23467813 · one of two readings recorded this

  • change in negative symptoms (SANS)

    decreases, p = 0.04, n = 120

    a significant decline in negative symptoms in the active treatment group (-0.17 per week; 95% CI, -0.34 to -0.01; p=.04)

    PMID 23467813 · one of two readings recorded this

  • change in negative symptoms (SANS)

    decreases, p = 0.02, n = 135

    Patients who received folate plus B12 exhibited a significant decline in negative symptoms (-0.19 change in SANS per week; 95% CI, -0.35 to -0.03; p=.02)

    PMID 23467813 · one of two readings recorded this

  • change in negative symptoms (SANS)

    no effect, p = 0.18, n = 120

    the placebo group (+0.16 per week; 95% CI, -0.07 to 0.39; p=.18)

    PMID 23467813 · one of two readings recorded this

  • change in negative symptoms (SANS)

    no effect, n = 135

    those who received placebo did not change (+0.02 per week; 95% CI, -0.21 to 0.24; p=88)

    PMID 23467813 · one of two readings recorded this

  • depression scores

    no effect, n = 135

    No significant effects of treatment were seen for depression scores

    PMID 23467813 · one of two readings recorded this

  • dietary folate and B12 intake, between-group difference

    no effect, p = 0.24

    Dietary folate and B12 intake did not differ significantly between treatment groups at baseline, week 8, or week 16 (p>.24)

    PMID 23467813 · one of two readings recorded this

  • negative symptoms of schizophrenia, Scale for the Assessment of Negative Symptoms (SANS) change per week; PANSS positive and total scores; Calgary Depression Rating Scale

    no effect, -0.21 per week; 95% CI, -0.49 to 0.07, p = 0.15

    Not recorded as a finding: the intervention held more than the compound

    Patients who received folate plus B12 exhibited a significant decline in negative symptoms (-0.19 change in SANS per week; 95% CI, -0.35 to -0.03; p=.02) and those who received placebo did not change (+0.02 per week; 95% CI, -0.21 to 0.24; p=88), although the difference between folate and placebo groups did not reach significance (-0.21 per week; 95% CI, -0.49 to 0.07; p=.15).

    PMID 23467813 · one of two readings recorded this

The whole record — 3,745 rows